Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001

June 27, 2024

Imvax, a national sponsor for Head for the Cure, has made significant strides in cancer research, recently announcing the completion of enrollment in their Phase 2b clinical trial of IGV-001. This milestone, coupled with successful financing efforts, underscores Imvax’s commitment to advancing cancer treatment and supporting critical causes like Head for the Cure.

Breakthrough in Cancer Immunotherapy

Imvax’s IGV-001 is an innovative immunotherapy aimed at treating glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer. The Phase 2b clinical trial, which has now completed enrollment, focuses on evaluating the efficacy and safety of this novel treatment. IGV-001 works by utilizing a personalized immunotherapy derived from the patient’s own tumor cells, designed to stimulate the immune system to target and destroy cancer cells.

“We are very pleased to announce full enrollment of the trial in less than 14 months, which speaks to both the clinical interest in this potential therapy and the efficient execution of our novel approach to treating GBM patients,” said John P. Furey, Imvax‘s Chief Executive Officer. “We are grateful to the investigators, patients, and their families for their commitment to this study and look forward to seeing top-line data next year. We are also delighted that the FDA has granted Fast Track designation to IGV-001. The last significant advancement in the standard of care for GBM – about an 8-week improvement in PFS – was nearly 20 years ago, highlighting the need for continued innovation and treatment options. We believe IGV-001 may offer meaningful clinical benefit for patients diagnosed with this deadly disease.”

Imvax and Head for the Cure: A Shared Mission

As a National Sponsor for Head for the Cure, Imvax shares a common goal of fighting brain cancer and supporting those affected by it. Head for the Cure is dedicated to raising awareness, funding research, and inspiring hope for brain cancer patients and their families. Imvax’s support and recent achievements highlight their unwavering commitment to making a meaningful impact in the fight against cancer.

                                          Learn more about Imvax here!